UroGen Other Current Liab vs Property Plant Equipment Analysis
URGN Stock | USD 13.30 0.25 1.85% |
UroGen Pharma financial indicator trend analysis is much more than just breaking down UroGen Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether UroGen Pharma is a good investment. Please check the relationship between UroGen Pharma Other Current Liab and its Property Plant Equipment accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.
Other Current Liab vs Property Plant Equipment
Other Current Liab vs Property Plant Equipment Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of UroGen Pharma Other Current Liab account and Property Plant Equipment. At this time, the significance of the direction appears to have strong relationship.
The correlation between UroGen Pharma's Other Current Liab and Property Plant Equipment is 0.75. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of UroGen Pharma, assuming nothing else is changed. The correlation between historical values of UroGen Pharma's Other Current Liab and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of UroGen Pharma are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Other Current Liab i.e., UroGen Pharma's Other Current Liab and Property Plant Equipment go up and down completely randomly.
Correlation Coefficient | 0.75 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Other Current Liab
Property Plant Equipment
Most indicators from UroGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Selling General Administrative is very stable compared to the past year. As of the 1st of June 2024, Tax Provision is likely to grow to about 1.2 M, while Issuance Of Capital Stock is likely to drop about 41.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 17.3M | 1.0M | 1.7M | 3.0M | Interest Income | 365K | 938K | 2.4M | 1.9M |
UroGen Pharma fundamental ratios Correlations
Click cells to compare fundamentals
UroGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
UroGen Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 202.4M | 122.0M | 119.7M | 136.2M | 178.3M | 98.8M | |
Total Current Liabilities | 19.5M | 21.4M | 22.4M | 23.9M | 31.2M | 32.8M | |
Total Stockholder Equity | 180.3M | 96.4M | 8.4M | (88.7M) | (65.2M) | (62.0M) | |
Net Tangible Assets | 180.3M | 96.4M | 8.4M | (89.4M) | (102.8M) | (97.6M) | |
Retained Earnings | (228.0M) | (356.5M) | (467.3M) | (577.1M) | (679.3M) | (645.4M) | |
Accounts Payable | 4.7M | 3.3M | 5.8M | 5.5M | 6.5M | 4.3M | |
Cash | 49.7M | 103.9M | 44.4M | 55.4M | 95.8M | 53.4M | |
Other Current Assets | 1.0M | 3.4M | 7.5M | 11.1M | 10.3M | 10.8M | |
Total Liab | 22.1M | 25.7M | 111.3M | 225.0M | 243.5M | 255.7M | |
Total Current Assets | 148.6M | 115.6M | 114.4M | 128.9M | 169.2M | 90.2M | |
Common Stock | 57K | 60K | 61K | 63K | 89K | 93.5K | |
Property Plant Equipment | 4.7M | 4.2M | 2.0M | 1.3M | 1.5M | 1.7M | |
Common Stock Shares Outstanding | 20.5M | 21.8M | 22.3M | 22.8M | 28.8M | 18.3M | |
Other Current Liab | 14.8M | 15.9M | 12.8M | 16.8M | 19.5M | 10.8M | |
Property Plant And Equipment Net | 4.7M | 4.2M | 3.1M | 3.7M | 2.4M | 2.6M | |
Net Debt | (47.1M) | (102.4M) | (44.0M) | 43.7M | 4.4M | 4.6M | |
Non Current Assets Total | 53.8M | 6.4M | 5.4M | 6.7M | 9.1M | 10.4M | |
Cash And Short Term Investments | 147.1M | 103.9M | 89.8M | 100.0M | 137.8M | 96.8M | |
Common Stock Total Equity | 57K | 60K | 61K | 63K | 72.5K | 45.9K | |
Liabilities And Stockholders Equity | 202.4M | 122.0M | 119.7M | 136.2M | 178.3M | 119.8M | |
Non Current Liabilities Total | 2.6M | 4.2M | 89.0M | 201.1M | 212.3M | 222.9M | |
Capital Surpluse | 408.0M | 452.5M | 475.7M | 487.8M | 561.0M | 307.7M | |
Other Stockholder Equity | 408.0M | 452.5M | 475.7M | 488.4M | 614.0M | 348.8M | |
Property Plant And Equipment Gross | 4.7M | 4.2M | 2.0M | 1.3M | 6.3M | 6.6M | |
Accumulated Other Comprehensive Income | 276K | 271K | (25K) | (107K) | 12K | 12.6K | |
Non Currrent Assets Other | 487K | 289K | 1.5M | 2.7M | 2.0M | 1.1M | |
Other Assets | 487K | 289K | 29.9K | 620K | 713K | 367.9K | |
Net Invested Capital | 180.3M | 96.4M | 8.4M | 8.2M | 33.3M | 55.5M | |
Net Working Capital | 129.2M | 94.2M | 92.0M | 105.0M | 138.0M | 112.3M | |
Retained Earnings Total Equity | (228.0M) | (356.5M) | (467.3M) | (577.1M) | (519.4M) | (545.4M) | |
Capital Stock | 57K | 60K | 61K | 63K | 89K | 68.6K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.Note that the UroGen Pharma information on this page should be used as a complementary analysis to other UroGen Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for UroGen Stock analysis
When running UroGen Pharma's price analysis, check to measure UroGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UroGen Pharma is operating at the current time. Most of UroGen Pharma's value examination focuses on studying past and present price action to predict the probability of UroGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UroGen Pharma's price. Additionally, you may evaluate how the addition of UroGen Pharma to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is UroGen Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.22) | Revenue Per Share 2.688 | Quarterly Revenue Growth 0.092 | Return On Assets (0.28) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.